These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21565498)

  • 21. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
    Hendriks BS; Seidl KM; Chabot JR
    BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
    Constantine KL; Mueller L; Metzler WJ; McDonnell PA; Todderud G; Goldfarb V; Fan Y; Newitt JA; Kiefer SE; Gao M; Tortolani D; Vaccaro W; Tokarski J
    J Med Chem; 2008 Oct; 51(19):6225-9. PubMed ID: 18771253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
    Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
    Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
    Wu JP; Wang J; Abeywardane A; Andersen D; Emmanuel M; Gautschi E; Goldberg DR; Kashem MA; Lukas S; Mao W; Martin L; Morwick T; Moss N; Pargellis C; Patel UR; Patnaude L; Peet GW; Skow D; Snow RJ; Ward Y; Werneburg B; White A
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4664-9. PubMed ID: 17576063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
    Crawford TD; Ndubaku CO; Chen H; Boggs JW; Bravo BJ; Delatorre K; Giannetti AM; Gould SE; Harris SF; Magnuson SR; McNamara E; Murray LJ; Nonomiya J; Sambrone A; Schmidt S; Smyczek T; Stanley M; Vitorino P; Wang L; West K; Wu P; Ye W
    J Med Chem; 2014 Apr; 57(8):3484-93. PubMed ID: 24673130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles.
    Kaila N; Green N; Li HQ; Hu Y; Janz K; Gavrin LK; Thomason J; Tam S; Powell D; Cuozzo J; Hall JP; Telliez JB; Hsu S; Nickerson-Nutter C; Wang Q; Lin LL
    Bioorg Med Chem; 2007 Oct; 15(19):6425-42. PubMed ID: 17664070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
    Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM
    J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
    Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
    Jasper A; Schepmann D; Lehmkuhl K; Vela JM; Buschmann H; Holenz J; Wünsch B
    Eur J Med Chem; 2009 Nov; 44(11):4306-14. PubMed ID: 19709783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel, selective and potent Chk2 inhibitors.
    Larson G; Yan S; Chen H; Rong F; Hong Z; Wu JZ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):172-5. PubMed ID: 17035018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
    Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
    J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
    Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
    Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
    Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
    Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.
    Revesz L; Schlapbach A; Aichholz R; Feifel R; Hawtin S; Heng R; Hiestand P; Jahnke W; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4715-8. PubMed ID: 20594847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.